949858--3/14/2008--SONUS_PHARMACEUTICALS

related topics

{product, candidate, development}

{product, liability, claim}

{acquisition, growth, future}

{property, intellectual, protect}

{stock, price, share}

{cost, regulation, environmental}

{customer, product, revenue}

{control, financial, internal}

{personnel, key, retain}

{product, market, service}

{stock, price, operating}

We will need additional capital in the future to support the continued development of our product candidates and to fund continuing operations. We may merge with or acquire other companies or drug candidates, and our failure to receive the anticipated benefits in these transactions could harm our business. Failure to satisfy NASDAQ Global Market listing requirements may result in our common stock being delisted from The NASDAQ Global Market. The success of our potential products in research and preclinical studies does not guarantee that these results will be replicated in humans. Our success is dependent on the proper management of our current and future business operations, and the expenses associated with them given our limited resources. We may never realize revenue from product commercialization. We may not achieve our projected development goals in the time frames we announce and anticipate. We have not yet commercialized any of our drug candidates; our ability to commercialize products is unproven. We have a history of operating losses which we expect will continue and we may never become profitable. Governmental regulatory requirements are lengthy and expensive and failure to obtain necessary approvals will prevent us from commercializing a product. If we lose our key personnel or are unable to attract and retain qualified scientific and management personnel, we may be unable to become profitable. Future U.S. or international legislative or administrative actions also could prevent or delay regulatory approval of our products. The development of oncology related pharmaceutical products is extremely competitive, and if we fail to compete effectively, it would negatively impact our business. We rely on third party suppliers and manufacturers to produce products that we develop and failure to retain such suppliers and manufacturers would adversely impact our ability to commercialize our products. If we fail to secure adequate intellectual property protection or become involved in an intellectual property dispute, it could significantly harm our financial results and ability to compete. Our commercial success will depend in part on not infringing patents issued to competitors. If we encounter difficulties enrolling patients in our clinical trials, our trials could be delayed or otherwise adversely affected. Reimbursement procedures and future healthcare reform measures are uncertain and may adversely impact our ability to successfully sell pharmaceutical products. If our products are not accepted by the medical community our business will suffer. The businesses in which we engage have a risk of product liability, and in the event of a successful suit against us, our business could be severely harmed. Since we use hazardous materials in our business, we may be subject to claims relating to improper handling, storage or disposal of these materials. Market volatility may affect our stock price and the value of an investment in our common stock may be subject to sudden decreases. We may face fluctuations in operating results. The impact of the recall by Bristol-Myers Squibb Pharmaceuticals of certain batches of Taxol.

Full 10-K form ▸

949858--3/14/2008--SONUS_PHARMACEUTICALS_INC